{"id":"cetuximab-erbitux","safety":{"commonSideEffects":[{"rate":"80-90","effect":"Acneiform rash"},{"rate":"25-30","effect":"Diarrhea"},{"rate":"20-25","effect":"Nausea"},{"rate":"15-20","effect":"Fatigue"},{"rate":"15-20","effect":"Vomiting"},{"rate":"3-5","effect":"Infusion reactions"},{"rate":"13-56","effect":"Hypomagnesemia"}]},"_chembl":{"chemblId":"CHEMBL1201577","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cetuximab binds to EGFR with high affinity, competitively inhibiting ligand binding and preventing receptor activation. This blocks downstream signaling pathways (MAPK and PI3K/AKT) that drive cell proliferation and survival. The antibody also recruits immune cells to mediate antibody-dependent cellular cytotoxicity (ADCC) against EGFR-expressing tumor cells.","oneSentence":"Cetuximab is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing tumor growth and survival signals.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:42.632Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (KRAS wild-type)"},{"name":"Head and neck squamous cell carcinoma"},{"name":"Non-small cell lung cancer (EGFR-expressing)"}]},"trialDetails":[{"nctId":"NCT01468896","phase":"PHASE1, PHASE2","title":"Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-10-26","conditions":"Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma","enrollment":23},{"nctId":"NCT05308446","phase":"PHASE2","title":"Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-07-19","conditions":"Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8","enrollment":84},{"nctId":"NCT05355701","phase":"PHASE1","title":"A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-07-05","conditions":"Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer","enrollment":267},{"nctId":"NCT06589804","phase":"PHASE3","title":"Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-03-27","conditions":"Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma","enrollment":158},{"nctId":"NCT06102902","phase":"PHASE1","title":"Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-05","conditions":"Metastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma","enrollment":30},{"nctId":"NCT06418724","phase":"PHASE2","title":"Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Melanoma and Skin Cancer Trials Limited","startDate":"2026-07-30","conditions":"Locally Advanced Cutaneous Squamous Cell Carcinoma","enrollment":27},{"nctId":"NCT07042295","phase":"PHASE2","title":"Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-23","conditions":"Locally Recurrent Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma","enrollment":86},{"nctId":"NCT05063552","phase":"PHASE2, PHASE3","title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-13","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":430},{"nctId":"NCT05039177","phase":"PHASE1, PHASE2","title":"A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies","status":"COMPLETED","sponsor":"Erasca, Inc.","startDate":"2021-09-20","conditions":"Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":101},{"nctId":"NCT04670679","phase":"PHASE1","title":"A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Erasca, Inc.","startDate":"2020-12-15","conditions":"Advanced or Metastatic Solid Tumors","enrollment":90},{"nctId":"NCT05863195","phase":"PHASE3","title":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-10-19","conditions":"Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8","enrollment":408},{"nctId":"NCT06997497","phase":"PHASE3","title":"A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-16","conditions":"Colon Adenocarcinoma, Rectal Adenocarcinoma","enrollment":477},{"nctId":"NCT06662786","phase":"PHASE3","title":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-10-18","conditions":"Colorectal Neoplasms","enrollment":1000},{"nctId":"NCT05217446","phase":"PHASE2","title":"A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-07-11","conditions":"Metastatic Colorectal Cancer","enrollment":107},{"nctId":"NCT06599502","phase":"PHASE1","title":"A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2024-10-18","conditions":"Advanced Solid Tumours, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":17},{"nctId":"NCT05253651","phase":"PHASE3","title":"A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2022-10-24","conditions":"Colorectal Neoplasms","enrollment":400},{"nctId":"NCT07286149","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-23","conditions":"Lung Neoplasm Malignant","enrollment":190},{"nctId":"NCT01810913","phase":"PHASE2, PHASE3","title":"Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-03-22","conditions":"Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7","enrollment":613},{"nctId":"NCT04892173","phase":"PHASE3","title":"JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC","status":"RECRUITING","sponsor":"Johnson & Johnson Enterprise Innovation Inc.","startDate":"2021-12-10","conditions":"Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged","enrollment":500},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT04590963","phase":"PHASE3","title":"Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-10-02","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":370},{"nctId":"NCT05985954","phase":"PHASE1","title":"Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-01-18","conditions":"Metastatic Colorectal Cancer","enrollment":27},{"nctId":"NCT07411599","phase":"PHASE1, PHASE2","title":"Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial (\"Chip-CRC Trial\")","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-07-29","conditions":"Colorectal Cancer, Peritoneal Metastases, Carcinomatosis","enrollment":28},{"nctId":"NCT03446157","phase":"PHASE2","title":"Palbociclib and Cetuximab in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2018-03-23","conditions":"Cancer of the Colon, Colon Cancer, Colon Neoplasms","enrollment":24},{"nctId":"NCT00939627","phase":"PHASE2","title":"Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-07","conditions":"Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer","enrollment":55},{"nctId":"NCT03370276","phase":"PHASE1, PHASE2","title":"Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-12-20","conditions":"Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oral Cavity","enrollment":95},{"nctId":"NCT07020221","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors","status":"RECRUITING","sponsor":"Verastem, Inc.","startDate":"2025-06-24","conditions":"Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer","enrollment":295},{"nctId":"NCT06412198","phase":"PHASE1, PHASE2","title":"A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-08-28","conditions":"Metastatic Colorectal Cancer, KRAS G12C Mutations","enrollment":31},{"nctId":"NCT05722327","phase":"PHASE1","title":"Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-12-06","conditions":"Colon Cancer, Colorectal Cancer","enrollment":24},{"nctId":"NCT07441681","phase":"PHASE3","title":"Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin","status":"NOT_YET_RECRUITING","sponsor":"NRG Oncology","startDate":"2027-01-06","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":454},{"nctId":"NCT06239220","phase":"PHASE2","title":"PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC","status":"RECRUITING","sponsor":"Glenn J. Hanna","startDate":"2024-02-16","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer","enrollment":25},{"nctId":"NCT07435311","phase":"PHASE1","title":"A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2020-06-15","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":118},{"nctId":"NCT07435324","phase":"PHASE3","title":"A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"R-Pharm","startDate":"2024-08-08","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":161},{"nctId":"NCT00003809","phase":"PHASE3","title":"Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1999-08-06","conditions":"Head and Neck Cancer","enrollment":""},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":330},{"nctId":"NCT07063212","phase":"PHASE2","title":"A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-07-02","conditions":"Squamous Cell Carcinoma of Head and Neck, Sinus Cancer, Nasal Cavity Cancer","enrollment":40},{"nctId":"NCT05041127","phase":"PHASE2","title":"Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-05-27","conditions":"Chordoma, Metastatic Chordoma, Unresectable Chordoma","enrollment":29},{"nctId":"NCT06750094","phase":"PHASE3","title":"A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-12-12","conditions":"Colorectal Neoplasms","enrollment":700},{"nctId":"NCT06369259","phase":"PHASE2","title":"Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-02-24","conditions":"Advanced Colorectal Cancer","enrollment":33},{"nctId":"NCT03365882","phase":"PHASE2","title":"S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2017-11-27","conditions":"Colon Adenocarcinoma, ERBB2 Gene Amplification, Rectal Adenocarcinoma","enrollment":240},{"nctId":"NCT02438722","phase":"PHASE2, PHASE3","title":"S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2015-05-07","conditions":"Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer","enrollment":174},{"nctId":"NCT03258554","phase":"PHASE2, PHASE3","title":"Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-04-03","conditions":"Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma","enrollment":196},{"nctId":"NCT07389265","phase":"PHASE3","title":"Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2025-10-01","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":480},{"nctId":"NCT02979977","phase":"PHASE2","title":"Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-03-24","conditions":"Squamous Cell Cancers of the Head and Neck","enrollment":50},{"nctId":"NCT07381764","phase":"PHASE2","title":"ROMANCE: \"Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer\"","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico Italia Meridionale","startDate":"2026-03-30","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":150},{"nctId":"NCT03082534","phase":"PHASE2","title":"Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2017-03-28","conditions":"HNSCC, Lip SCC, Oral Cavity Cancer","enrollment":78},{"nctId":"NCT05040568","phase":"PHASE1","title":"A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-02-28","conditions":"Colon Cancer, Resected Stage","enrollment":15},{"nctId":"NCT05710406","phase":"PHASE2, PHASE3","title":"Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-08-16","conditions":"Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Stage IIB Colon Cancer AJCC v8","enrollment":1},{"nctId":"NCT05584670","phase":"PHASE1, PHASE2","title":"A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Sanofi","startDate":"2022-11-29","conditions":"Solid Tumor","enrollment":542},{"nctId":"NCT06358430","phase":"PHASE1","title":"Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-12-02","conditions":"Colorectal Cancer, Minimal Residual Disease","enrollment":42},{"nctId":"NCT04229459","phase":"PHASE2","title":"Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baruch Brenner","startDate":"2020-02-16","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":12},{"nctId":"NCT03290937","phase":"PHASE1","title":"Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-12-27","conditions":"Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8","enrollment":34},{"nctId":"NCT07318805","phase":"PHASE1","title":"A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-12-16","conditions":"Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer","enrollment":260},{"nctId":"NCT02270814","phase":"PHASE2","title":"Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2015-02-02","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Head and Neck","enrollment":74},{"nctId":"NCT04616183","phase":"PHASE1, PHASE2","title":"LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-12-02","conditions":"Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma","enrollment":46},{"nctId":"NCT07216105","phase":"PHASE1","title":"FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Fate Therapeutics","startDate":"2025-11-04","conditions":"Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer","enrollment":113},{"nctId":"NCT05959356","phase":"PHASE2","title":"Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-11-09","conditions":"Metastatic Colorectal Cancer","enrollment":198},{"nctId":"NCT01154920","phase":"PHASE2","title":"Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-07-09","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":128},{"nctId":"NCT06447987","phase":"PHASE1","title":"Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-11-06","conditions":"Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia","enrollment":24},{"nctId":"NCT06764771","phase":"PHASE1","title":"A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-03-25","conditions":"Advanced Malignant Tumors","enrollment":437},{"nctId":"NCT05956821","phase":"PHASE1, PHASE2","title":"Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age","status":"RECRUITING","sponsor":"University of Miami","startDate":"2025-06-19","conditions":"Glioblastoma Multiforme, Anaplastic Astrocytoma, Fibrillary Astrocytomas","enrollment":20},{"nctId":"NCT04835142","phase":"PHASE3","title":"Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC","status":"COMPLETED","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2020-12-31","conditions":"Metastatic Colorectal Cancer","enrollment":688},{"nctId":"NCT04428151","phase":"PHASE2","title":"Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-08-06","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":408},{"nctId":"NCT06912087","phase":"PHASE1","title":"Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-09-29","conditions":"Head and Neck Neoplasms, Carcinoma, Squamous Cell, Neoplasm Recurrence, Local","enrollment":36},{"nctId":"NCT04017650","phase":"PHASE1, PHASE2","title":"Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-06-14","conditions":"BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma","enrollment":38},{"nctId":"NCT05200442","phase":"PHASE1, PHASE2","title":"A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2022-08-22","conditions":"Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic","enrollment":53},{"nctId":"NCT06046482","phase":"PHASE2","title":"Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-11-28","conditions":"Head Neck, Squamous Cell Carcinoma of Head and Neck","enrollment":4},{"nctId":"NCT01552434","phase":"PHASE1","title":"Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-03-16","conditions":"Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma","enrollment":155},{"nctId":"NCT07204574","phase":"PHASE1, PHASE2","title":"The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-05-14","conditions":"CRC","enrollment":40},{"nctId":"NCT04776655","phase":"PHASE3","title":"Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB","status":"RECRUITING","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2021-04-30","conditions":"Colorectal Cancer, Metastatic Colorectal Cancer, RAS Mutation","enrollment":280},{"nctId":"NCT05271604","phase":"PHASE2","title":"A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"BioAtla, Inc.","startDate":"2022-12-13","conditions":"Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck","enrollment":42},{"nctId":"NCT01326468","phase":"NA","title":"Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2011-12-08","conditions":"Head and Neck Cancer","enrollment":""},{"nctId":"NCT04956640","phase":"PHASE1, PHASE2","title":"Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2021-07-19","conditions":"Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms","enrollment":540},{"nctId":"NCT05104567","phase":"PHASE2","title":"A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-12-09","conditions":"Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma","enrollment":138},{"nctId":"NCT05061420","phase":"PHASE2","title":"A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)","status":"TERMINATED","sponsor":"Sanofi","startDate":"2021-10-08","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":59},{"nctId":"NCT07183865","phase":"PHASE2","title":"Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-09","conditions":"Locally Recurrent Rectal Cancer","enrollment":44},{"nctId":"NCT01787500","phase":"PHASE1","title":"Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-02-15","conditions":"BRAF NP_004324.2:p.V600X, KRAS wt Allele, Metastatic Malignant Solid Neoplasm","enrollment":33},{"nctId":"NCT05775900","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2023-02-01","conditions":"Metastatic Colorectal Cancer","enrollment":24},{"nctId":"NCT04966481","phase":"PHASE3","title":"Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2022-04-06","conditions":"HPV-unrelated Head and Neck Squamous Cell Carcinoma","enrollment":81},{"nctId":"NCT04607421","phase":"PHASE3","title":"A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-12-21","conditions":"Neoplasms","enrollment":831},{"nctId":"NCT05743036","phase":"PHASE1","title":"ZN-c3 in Adult Participants With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc","startDate":"2023-02-27","conditions":"Metastatic Colorectal Cancer","enrollment":44},{"nctId":"NCT03493048","phase":"PHASE2","title":"Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-04-15","conditions":"Colorectal Cancer, Liver Metastases","enrollment":146},{"nctId":"NCT06024174","phase":"PHASE1, PHASE2","title":"A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2023-11-09","conditions":"Advanced Solid Tumors","enrollment":5},{"nctId":"NCT01726309","phase":"","title":"Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4","status":"TERMINATED","sponsor":"Cancer Trials Ireland","startDate":"2011-05","conditions":"Colorectal Cancer, Non-Small Cell Lung Cancer","enrollment":161},{"nctId":"NCT06980454","phase":"PHASE1","title":"Phase I PK Comparison of HLX05 vs. Erbitux® in Healthy Chinese Males: Safety, Immunogenicity, and Pharmacokinetics","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2025-06-04","conditions":"Cancer, mCRC","enrollment":322},{"nctId":"NCT07012954","phase":"PHASE1, PHASE2","title":"ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-06-01","conditions":"Colorectal Cancer Metastatic","enrollment":64},{"nctId":"NCT04616196","phase":"PHASE1, PHASE2","title":"Study of NKTR 255 in Combination With Cetuximab in Solid Tumors","status":"COMPLETED","sponsor":"Nektar Therapeutics","startDate":"2020-10-30","conditions":"Head and Neck Squamous Cell Carcinoma, Colorectal Cancer","enrollment":25},{"nctId":"NCT00324415","phase":"PHASE2","title":"Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2006-09","conditions":"Anal Cancer","enrollment":45},{"nctId":"NCT06988852","phase":"PHASE2","title":"FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2023-05-01","conditions":"Colorectal Liver Metastasis (CRLM)","enrollment":300},{"nctId":"NCT05312398","phase":"PHASE2","title":"CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2021-07-15","conditions":"Metastatic Colorectal Adenocarcinoma","enrollment":219},{"nctId":"NCT04278092","phase":"PHASE2","title":"Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2020-02-10","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":57},{"nctId":"NCT03428958","phase":"PHASE1, PHASE2","title":"A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment","status":"COMPLETED","sponsor":"NuCana plc","startDate":"2018-10-05","conditions":"Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma","enrollment":111},{"nctId":"NCT02934529","phase":"PHASE3","title":"Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2015-03","conditions":"Metastatic Colorectal Cancer","enrollment":673},{"nctId":"NCT05004350","phase":"PHASE2","title":"A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2021-09-14","conditions":"BRAF V600E, Metastatic Colorectal Cancer","enrollment":107},{"nctId":"NCT03389477","phase":"PHASE2","title":"Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2018-04-27","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":26},{"nctId":"NCT06064877","phase":"PHASE3","title":"A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"AVEO Pharmaceuticals, Inc.","startDate":"2024-01-11","conditions":"Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":410},{"nctId":"NCT02800486","phase":"PHASE2","title":"Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2016-05","conditions":"Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma","enrollment":37},{"nctId":"NCT03646461","phase":"PHASE2","title":"Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Diego","startDate":"2018-10-17","conditions":"Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck","enrollment":5},{"nctId":"NCT03498378","phase":"PHASE1","title":"Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kathryn Gold","startDate":"2018-06-06","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":24},{"nctId":"NCT02128906","phase":"PHASE2","title":"Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design","status":"RECRUITING","sponsor":"Christopher Wilke","startDate":"2013-12-23","conditions":"Squamous Cell Carcinoma","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Cetuximab/Erbitux","genericName":"Cetuximab/Erbitux","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cetuximab, also known as Erbitux, is an antibody that targets and inhibits the epidermal growth factor receptor (EGFR), a protein involved in cell growth and division. It is used to treat various types of cancer, including squamous cell carcinoma of the head and neck, non-small-cell lung carcinoma, and other lung cancers.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}